Stability Study of 0.5 g/mL Urea Oral Solution in InOrpha®
Urea is recommended in the 2nd line treatment in moderate to severe hyponatraemia induced by syndrome of inappropriate antidiuretic hormone secretion (SIADH), when water restriction is insufficient. A posology of 0.25-0.5 g/kg daily is suggested. A usual but inadequate urea oral preparation, i. e. 1...
Saved in:
Main Authors: | Bourbon Johan (Author), Dory Anne (Author), Perello Laurent (Author), Belotti Laure (Author), Reisz Fanny (Author), Ubeaud-Sequier Genevieve (Author), Gourieux Bénédicte (Author) |
---|---|
Format: | Book |
Published: |
De Gruyter,
2019-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Stability of refrigerated miglustat after preparation in InOrpha® flavored suspending excipient for compounding of oral solutions and suspensions
by: Riahi S, et al.
Published: (2015) -
Physicochemical stability of urea-containing Mitomycin C preparations in glass vials (1.0 mg/mL) and plastic syringes (2.0, 0.4, 0.2 mg/mL)
by: Almasi Jannik, et al.
Published: (2023) -
0.5% hyperbaric bupivacaine - Do we still need a 4 ml ampoule?
by: Rakhee Goyal, et al.
Published: (2012) -
Ramosetron 3.0 μg/mL Combining with Dexamethasone (0.05, 0.1, 0.2 mg/mL) in Infusion Solutions: A Physicochemical Stability Study
by: Baoxia Fang, et al.
Published: (2024) -
Ropivacaine 0.025% mixed with fentanyl 3.0 μg/ml and epinephrine 0.5 μg/ml is effective for epidural patient-controlled analgesia after cesarean section
by: Shaul Cohen, et al.
Published: (2015)